Ophthalmology · PresbyopiaTrial Updateclinicalmid-term

Study Compares Laser Blended Vision and Monovision LASIK for Presbyopia

The ongoing clinical trial comparing laser blended vision (LBV) with conventional monovision LASIK for presbyopia could significantly influence treatment preferences and market dynamics. A favorable outcome for LBV may lead to a shift in clinical practice and affect the positioning of existing LASIK technologies.

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/19/2026, 6:31:18 PM

Assessment confidence: 35% · The main uncertainty is the absence of ranked evidence — conclusions rely primarily on signal intelligence.

Executive Thesis

Strategic Assessment

If LBV proves superior, it could shift clinical practice and impact product positioning for LASIK technologies. The strongest clinical anchor is MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) (ClinicalTrials.gov), weak alignment to signal sub-indication and entities. If LBV demonstrates superior outcomes, it could capture market share from conventional LASIK procedures, impacting revenue streams for companies involved in presbyopia correction.

Competitive Pressure

The most relevant competitive pressure comes from The outcome may influence treatment preferences and market dynamics for presbyopia correction options..

Regulatory Outlook

Regulatory risk is concentrated around The results of this trial may inform future regulatory submissions and labeling for LASIK technologies, depending on the safety and efficacy outcomes observed..

Key Risks

Elevated medium regulatory exposure for presbyopia treatment market could delay market entry or constrain labeling if agency review intensifies.
Evidence gap: no medium- or high-relevance regulatory precedents in ingested corpus.

Key Opportunities

If LBV demonstrates superior outcomes, it could capture market share from conventional LASIK procedures, impacting revenue streams for companies involved in presbyopia correction.
If LBV proves superior, it could shift clinical practice and impact product positioning for LASIK technologies.

What Would Change This Assessment

This becomes more urgent if Monitor results regarding visual outcomes and safety profiles post-surgery, expected at 6 months follow-up.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

Guidance: Clinical trials for medicines: roles and responsibilities
MHRAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Drug Trials Snapshots: YARTEMLEA
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Drug Trials Snapshots: PALSONIFY
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Office of New Drugs Custom Medical Queries (OCMQs) for Safety Signal Detection in Clinical Trial Data - 06/23/2026
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Post Market Study for VasQ, an External Support Implant for Arteriovenous Fistula
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Efficacy of Gamified Blended Mindfulness Program to Reduce Burnout, Stress, and Anxiety in Nursing Students: A Randomized Controlled Trial
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Mirena for the Treatment of Nonatypical Endometrial Hyperplasia for 6 Months
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Trial of Treatments for COVID-19 in Hospitalized Adults
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
LASER VERSUS CRYSTALLIZED PHENOL IN PILONIDAL SINUS DISEASE
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

No evidence in this category.

Do subjective and objective baseline sleep disturbances predict post-traumatic stress disorder treatment response? A secondary analysis of a randomized controlled trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Amino acid infusion and acute kidney injury after aortic surgery: a multicenter observational study with target trial emulation.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Cost-effectiveness analysis of apixaban compared with other oral anticoagulants for the treatment of non-valvular atrial fibrillation in Belgian healthcare setting.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Adaption of a posttraumatic stress disorder intervention for patients who use stimulants and opioids in the opioid treatment programme setting.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Elevated ESR2 and BRCA1 gene expression in adenomyosis associated with endometrial cancer: a pilot study.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Comparative efficacy, recovery, and pigmentary safety of radiofrequency microneedling and fractional carbon dioxide laser for facial atrophic acne scars: a prospective randomized split-face trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

presbyopia treatment market

Commercial impact

medium

If LBV demonstrates superior outcomes, it could capture market share from conventional LASIK procedures, impacting revenue streams for companies involved in presbyopia correction.

Regulatory impact